Evonik Industries Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Evonik Industries Bundle
Unlock Strategic Clarity
Curious about Evonik Industries' product portfolio performance? This glimpse into their BCG Matrix reveals which segments are poised for growth (Stars) and which are generating stable revenue (Cash Cows). But to truly unlock strategic advantages, you need the full picture.
Gain a comprehensive understanding of Evonik's market position with the complete BCG Matrix. Discover detailed quadrant placements, data-backed insights into their Stars, Cash Cows, Dogs, and Question Marks, and actionable recommendations for optimizing your investment strategy.
Don't miss out on the critical intelligence needed to navigate Evonik's diverse offerings. Purchase the full BCG Matrix report today and equip yourself with the knowledge to make informed decisions and drive future success.
Stars
Next Generation Solutions Portfolio
Evonik's Next Generation Solutions represent a significant strategic push, focusing on products that offer clear sustainability benefits to customers. These innovative offerings are already making a substantial impact on the company's financial performance.
In 2024, these forward-looking solutions contributed a remarkable 45 percent to Evonik's total Group sales. This strong showing highlights not only their current market relevance but also their rapid growth and increasing acceptance by a wide range of industries.
Looking ahead, Evonik has set an ambitious target to increase the share of Next Generation Solutions to over 50 percent of Group sales by the year 2030. This objective underscores the company's commitment to continued investment in these areas and its expectation of achieving a leading market position.
Lipids for mRNA and Gene Therapies
Evonik Industries is heavily investing in lipids for mRNA and gene therapies, a key growth driver within its Health Care segment. This strategic focus targets the burgeoning pharmaceutical market, where innovative drug delivery is paramount.
The company's dedication to this high-value sector is underscored by its establishment of a German facility to produce lipid nanoparticles for BioNTech. This move is expected to solidify Evonik's market leadership and capitalize on the accelerating demand for advanced therapeutic solutions.
Biosurfactants (e.g., Rhamnolipids)
Evonik is making waves in the bio-based chemicals market, particularly with its rhamnolipids. The company opened the world's first industrial-scale rhamnolipid plant in Slovakia in May 2024, a significant move in this sector.
These advanced biosurfactants are positioned within Evonik's 'Advance Precision Biosolutions' segment, a key innovation area focused on high-growth opportunities. Rhamnolipids are finding application in personal care, cleaning products, and other expanding markets.
This strategic investment highlights Evonik's commitment to sustainable solutions and its ambition to secure a considerable share of the expanding market for environmentally friendly chemicals.
Membranes for Gas Separation (Biomethane/Hydrogen)
Evonik's membranes for gas separation, particularly for biomethane purification and hydrogen production, represent a significant opportunity within its 'Accelerate Energy Transition' innovation growth area. The company is actively expanding its production capabilities to meet the burgeoning demand driven by global shifts towards green energy and decarbonization.
This strategic focus positions Evonik within a high-growth market, capitalizing on the increasing need for advanced and sustainable gas separation solutions. The market for hydrogen, in particular, is experiencing rapid expansion, with projections indicating substantial growth through 2030 and beyond, fueled by government incentives and industrial decarbonization efforts.
- Market Growth: The global hydrogen market is expected to reach hundreds of billions of dollars by 2030, with membranes playing a key role in production efficiency.
- Biomethane Potential: Advancements in biomethane purification are crucial for renewable natural gas (RNG) adoption, a sector also seeing significant investment.
- Technology Advancement: Evonik's investment signals a commitment to leading-edge membrane technology that offers higher separation efficiency and lower energy consumption compared to traditional methods.
- Sustainability Focus: These membranes directly contribute to reducing greenhouse gas emissions by enabling cleaner energy sources and more efficient industrial processes.
Specialty Additives for High-Performance Applications
Evonik's Specialty Additives division is a shining example of a star in the BCG matrix. In the first quarter of 2025, this segment saw a significant uptick in sales. This growth was fueled by robust demand from key sectors, including coatings, crosslinkers, and the crucial oil additives market.
These high-performance additives are not just ingredients; they are essential for elevating product performance and improving sustainability. Industries such as automotive, construction, and consumer goods rely heavily on these advanced materials to achieve superior characteristics. Evonik's commitment to innovation within this division, coupled with increasing market needs for sophisticated functionalities, firmly places Specialty Additives in the star category.
- Q1 2025 Sales Growth: Increased demand in coatings, crosslinkers, and oil additives.
- Key Industries Served: Automotive, construction, and consumer goods benefit from enhanced product characteristics and sustainability.
- Market Position: Evonik holds a strong position due to continuous innovation and growing market demand for advanced functionalities.
Evonik's Additives: A 'Star' in the BCG Matrix
Evonik's Specialty Additives division is a standout performer, embodying the characteristics of a 'Star' in the BCG matrix. This segment experienced robust sales growth in early 2025, driven by strong demand across coatings, crosslinkers, and oil additives.
These high-performance additives are crucial for enhancing product performance and sustainability in sectors like automotive, construction, and consumer goods. Evonik's ongoing innovation and the increasing market need for sophisticated functionalities solidify this division's star status.
The strong performance of Specialty Additives, with its high market share and growth potential, aligns perfectly with the strategic definition of a star. This segment is a key contributor to Evonik's overall growth strategy, demonstrating significant market traction and future promise.
| Segment | BCG Category | Key Growth Drivers (Early 2025) | Market Position |
|---|---|---|---|
| Specialty Additives | Star | Coatings, Crosslinkers, Oil Additives | High Market Share, Strong Innovation |
What is included in the product
Detailed Word Document
Evonik's BCG Matrix analysis categorizes its business units based on market share and growth, guiding strategic decisions for investment and resource allocation.
Customizable Excel Spreadsheet
The Evonik Industries BCG Matrix provides a clear, one-page overview of each business unit's strategic position, relieving the pain point of complex portfolio analysis.
Cash Cows
Established Animal Nutrition Products
Evonik's established animal nutrition products are a prime example of a Cash Cow. This segment, part of the Nutrition & Care division, has shown robust performance, with sales growth and favorable pricing trends boosting earnings in Q1 2025.
Operating in a stable, non-cyclical market, Evonik commands leading positions, allowing it to generate substantial cash flow. This consistent profitability and market strength solidify its role as a reliable cash generator for the company.
Core Specialty Additives for Mature Industries
Evonik's core specialty additives, especially those catering to mature sectors like traditional paints and coatings, are strong cash cows. These established product lines benefit from deep market penetration and significant barriers to entry, ensuring a steady stream of income.
For instance, Evonik's crosslinkers for powder coatings, a segment with decades of development, continue to generate reliable profits. In 2024, the global market for specialty additives was valued at approximately $25 billion, with mature applications representing a substantial portion of this, underscoring the stability of these cash cow products for Evonik.
Mature Care Solutions Portfolio
Evonik's Care Solutions business line, a key component of its portfolio, operates within the stable and mature markets of personal care, home care, and textile cleaning. This segment is characterized by consistent demand and strong profit margins, reflecting Evonik's established expertise and market presence.
In 2024, the Care Solutions segment continued to be a reliable generator of cash for Evonik, contributing significantly to the company's overall financial stability. This consistent cash flow is crucial, enabling Evonik to strategically allocate resources towards its growth-oriented business areas.
Silicone and Amine Platforms
Evonik's Silicone and Amine platforms are strong cash cows, representing mature businesses that generate consistent revenue. The company's significant investment of over €100 million between 2022 and 2024 in modular expansion for these platforms highlights their foundational importance and ongoing optimization.
These platforms are critical to numerous industrial applications, demonstrating their established market position and reliability. Their continuous development ensures they remain efficient and profitable, contributing stable cash flows to Evonik's overall financial health.
- Established Market Presence: The Silicone and Amine platforms serve diverse industrial needs, solidifying their mature status.
- Strategic Investment: Over €100 million invested from 2022-2024 in modular expansion underscores their importance.
- Reliable Cash Flow: These foundational businesses consistently generate dependable revenue for Evonik.
- Broad Application Scope: Their utility across various sectors confirms their robust and enduring market relevance.
Infrastructure Services for Production Sites
Evonik's infrastructure services for production sites, following its Technology & Infrastructure division reorganization, are now a core strategic technology expertise. This internal function acts as a cash cow within the BCG matrix, generating consistent revenue through its essential, captive market role.
Operating with high efficiency, these services provide critical support to all production units, directly contributing to cost control and robust cash generation for Evonik. For instance, in 2024, Evonik continued to invest in optimizing site infrastructure, aiming for enhanced energy efficiency and operational reliability, which directly translates to cost savings and stable cash flow from these services.
- Captive Market: Provides essential services to all of Evonik's production facilities, ensuring a stable demand.
- High Efficiency: Focuses on operational cost control and optimized resource allocation.
- Cash Generation: Contributes significantly to stable cash flow through reliable service provision.
- Strategic Importance: Underpins the operational success and cost-effectiveness of all production sites.
Cash Cows: Evonik's Stable Revenue Streams
Evonik's established animal nutrition products are a prime example of a Cash Cow, demonstrating robust performance with favorable pricing trends boosting earnings in Q1 2025.
Operating in a stable market, Evonik commands leading positions, generating substantial cash flow from these reliable products.
Core specialty additives, particularly for mature sectors like traditional paints and coatings, are also strong cash cows due to deep market penetration and high barriers to entry.
For instance, Evonik's crosslinkers for powder coatings, a segment with decades of development, continue to generate reliable profits, contributing to the overall stability of these cash cow products.
| Business Segment | BCG Matrix Category | Key Characteristics | 2024 Relevance |
|---|---|---|---|
| Animal Nutrition | Cash Cow | Established market, leading positions, stable demand | Robust performance, favorable pricing |
| Specialty Additives (e.g., Powder Coatings) | Cash Cow | Mature sectors, deep market penetration, high barriers | Consistent profitability, reliable income |
| Care Solutions | Cash Cow | Personal care, home care, textile cleaning, stable demand | Reliable cash generator, financial stability |
| Silicone and Amine Platforms | Cash Cow | Mature businesses, broad industrial applications | Consistent revenue, ongoing optimization |
| Infrastructure Services | Cash Cow | Captive market, high efficiency, essential support | Stable cash flow, cost control |
What You’re Viewing Is Included
Evonik Industries BCG Matrix
The Evonik Industries BCG Matrix preview you see is the exact, unwatermarked document you will receive upon purchase. This comprehensive report is meticulously crafted to provide actionable insights into Evonik's product portfolio, categorizing each business unit as a Star, Cash Cow, Question Mark, or Dog. You'll gain a clear strategic overview, enabling informed decision-making for resource allocation and future growth initiatives. This professional-grade analysis is ready for immediate integration into your business planning and strategic discussions.
Dogs
Superabsorbent Polymers Business
Evonik Industries completed the divestment of its superabsorbent polymers (SAP) business in August 2024, selling it to International Chemical Investors Group (ICIG). This move aligns with Evonik's strategy to focus on its core, higher-growth specialty chemicals segments.
The SAP business, historically a significant player, was likely categorized as a 'Dog' in Evonik's BCG Matrix. This classification suggests it operated in a mature or declining market with limited growth potential and potentially faced intense competition, impacting its market share and profitability within Evonik's broader portfolio.
While specific financial figures for the SAP unit's performance leading up to the divestment are not publicly detailed by Evonik, such businesses often exhibit stable but low revenue growth. The sale price, while undisclosed, would reflect market valuations for such assets, often based on EBITDA multiples in the specialty chemicals sector, which can range from 5-10x depending on market conditions and business specifics.
Keto Acids Production (Hanau)
Evonik's keto acids production in Hanau, a business line serving pharmaceutical applications, is slated for discontinuation by the close of 2025. This move will impact around 260 employees, signaling a strategic pivot away from this particular segment due to its perceived limited future growth prospects or inadequate market standing within the company's evolving strategic framework.
Polyester Business for Coatings and Adhesives
Evonik Industries is divesting its polyester business focused on coatings and adhesives, a segment that brought in approximately €150 million in annual revenue. This strategic decision signals that, despite its revenue generation, this particular business unit was not identified as a key driver for future growth within Evonik's portfolio.
The sale suggests the polyester business may have encountered limitations in market expansion or struggled to maintain a competitive edge relative to other Evonik operations. This aligns with a typical BCG Matrix assessment where units not demonstrating strong growth potential or market share might be considered for divestment to reallocate resources to more promising ventures.
Existing Polyolefins Business
Evonik Industries is strategically divesting its polyolefins business, a move that places this segment squarely in the 'Dog' quadrant of the BCG Matrix. This business line is being integrated into Evonik's C4 chain operations before its eventual sale, signaling a clear intent to exit this market.
The decision to sell highlights that polyolefins are considered a low-priority, non-core asset within Evonik's broader portfolio. This often indicates a low market share within a mature or even declining industry segment, where growth prospects are limited and competitive intensity is high.
- Low Market Share: The polyolefins segment likely struggles to command a significant portion of the overall polyolefins market.
- Mature/Declining Market: The industry for polyolefins may be characterized by slow growth or even contraction, making it less attractive for investment.
- Divestment Strategy: Evonik's action to sell the business underscores its focus on optimizing its asset base and concentrating on more promising growth areas.
- Strategic Realignment: This move is part of a larger effort to streamline operations and enhance overall profitability by shedding underperforming or non-strategic units.
C4 Chemicals and Isononanol
Evonik Industries has placed its C4 Chemicals and Isononanol business units under strategic review as part of a broader divestment program. This move suggests these segments are viewed as non-core assets within the company's portfolio.
The C4 Chemicals and Isononanol segments likely fall into the Dogs category of the BCG Matrix. This classification implies they operate in low-growth markets and hold a relatively small market share, making them less attractive for future investment.
- Divestment Strategy: Evonik's sale of its third Performance Materials business, encompassing C4 Chemicals and Isononanol, signals a strategic shift away from these product lines.
- BCG Matrix Placement: These businesses are categorized as Dogs due to their low market share in slow-growing industries.
- Financial Implications: Divesting these segments is intended to free up capital and resources for more promising growth areas within Evonik's portfolio.
- Market Context: The C4 chemicals market, while essential, faces evolving demand dynamics and competitive pressures, contributing to its classification as a lower-growth segment.
Evonik's Strategic Shift: Shedding 'Dogs' for Growth
Evonik's divestment of its superabsorbent polymers (SAP) business in August 2024 to ICIG exemplifies a 'Dog' in the BCG Matrix. This business, likely operating in a mature market with limited growth, was sold to focus on higher-growth specialty chemicals.
Similarly, the planned discontinuation of keto acids production by the end of 2025 and the divestment of the polyester business for coatings and adhesives, which generated around €150 million annually, also point to 'Dog' classifications. These moves reflect a strategic decision to exit segments with perceived limited future growth or competitive challenges.
The polyolefins business, now being integrated for sale, and the C4 Chemicals and Isononanol units under strategic review, are further examples of Evonik's 'Dog' divestments. These segments are characterized by low market share in slow-growing industries, indicating a strategic pivot to optimize assets and reallocate resources to more promising ventures.
These divestments are part of Evonik's broader strategy to streamline its portfolio and enhance profitability by shedding underperforming or non-strategic units, allowing for greater investment in core, high-growth specialty areas.
Question Marks
Emerging Applications within Advance Precision Biosolutions
Within Evonik's Advance Precision Biosolutions, beyond the growing interest in rhamnolipids, other emerging biotechnologies are in their infancy. These innovations focus on enhancing human health, promoting resource efficiency, and safeguarding the environment, addressing critical societal demands.
These nascent solutions, while promising for high-growth markets, currently hold minimal market share. Significant capital infusion is necessary for their expansion and to elevate them to potential market leaders in the future. For instance, Evonik's investment in its biotechnology pipeline reflects this strategy, aiming to cultivate future growth drivers.
New Solutions in Accelerate Energy Transition
Evonik is investing heavily in its 'Accelerate Energy Transition' segment, exploring cutting-edge carbon capture technologies and innovative hydrogen production methods. These ventures target emerging, high-potential markets, though their current market share remains minimal, demanding substantial research and development funding.
In 2024, Evonik's commitment to this area is underscored by significant capital allocation towards these nascent technologies, aiming to establish a strong foothold in the rapidly evolving energy landscape. The company is focusing on solutions that promise to significantly reduce carbon emissions and enhance the efficiency of green energy production.
Developing Technologies for Enable Circular Economy
Evonik's 'Enable Circular Economy' innovation area targets closing material loops with technologies like advanced catalyst recycling and better polyurethane and rubber recycling. This aligns with strong market demand for circular solutions, though these innovations are likely in their nascent stages of market penetration.
Significant investment is crucial for these ventures to achieve substantial market share and demonstrate commercial success. For instance, the global circular economy market was valued at approximately $2.4 trillion in 2023 and is projected to reach $4.7 trillion by 2030, highlighting the immense growth potential Evonik is tapping into.
Niche Drug Delivery Systems and Cell Culture Ingredients
Niche drug delivery systems and cell culture ingredients represent Evonik's strategic push into specialized, high-growth areas within the pharmaceutical and biotech sectors. These innovations, such as advanced lipid-based systems for mRNA vaccines or specialized media for cell therapy production, cater to specific therapeutic needs and advanced manufacturing processes. For instance, Evonik's lipid excipients are crucial for the delivery of mRNA therapies, a market that saw significant growth and investment in 2023 and is projected to continue expanding.
- Targeted Development: Evonik is focusing on highly specialized drug delivery systems and novel cell culture ingredients for niche pharmaceutical and biotech markets.
- Market Position: While these products serve high-growth segments, their current market share within these specific niches is likely modest, requiring focused investment.
- Growth Potential: The development of these advanced materials supports the burgeoning fields of personalized medicine and advanced biologics, indicating strong future growth prospects.
- Strategic Investment: Continued investment in research and development is essential to capture the significant potential of these specialized offerings and expand market penetration.
New Additive Functionalities and Technology Platforms
Evonik's Specialty Additives segment is actively expanding its offerings by integrating novel functionalities and advanced technology platforms. These developments are designed to address evolving market demands and unlock performance improvements in diverse applications, positioning them as potential future growth drivers.
These innovations, while promising, typically begin with a nascent market presence. Consequently, they require substantial investment in marketing and research and development to gain traction and achieve widespread market acceptance. For instance, Evonik's focus on sustainable additive solutions, such as bio-based materials and circular economy-compatible products, represents a key area of investment for new functionalities.
- New Additive Functionalities: Evonik is developing additives that offer enhanced properties like improved UV resistance, flame retardancy, and specific rheological behavior.
- Technology Platforms: The company is investing in digital platforms and advanced formulation technologies to support the integration and application of its new additives.
- Market Entry Strategy: New functionalities and platforms typically enter the market with a low market share, necessitating significant R&D and marketing expenditure.
- Growth Potential: These innovations are strategic investments targeting emerging market needs and represent significant long-term growth opportunities for Evonik's Specialty Additives business.
Evonik's High-Growth, Low-Share Bets: Question Marks
Evonik's focus on emerging biotechnologies within Advance Precision Biosolutions, such as rhamnolipids, along with its investments in carbon capture and hydrogen production under 'Accelerate Energy Transition,' and its circular economy initiatives, all represent Question Marks in the BCG Matrix. These ventures are characterized by high growth potential but currently hold minimal market share, demanding substantial capital for research, development, and market penetration.
These nascent technologies, while addressing critical societal needs and tapping into expanding markets like the circular economy (valued at approximately $2.4 trillion in 2023 and projected to reach $4.7 trillion by 2030), require significant financial backing to mature. Evonik's strategic allocation of capital in 2024 to these areas underscores the company's long-term vision to cultivate future growth drivers in these promising, albeit early-stage, sectors.
Similarly, niche drug delivery systems and novel cell culture ingredients in the pharmaceutical and biotech sectors, along with new additive functionalities and technology platforms in Specialty Additives, also fall into the Question Mark category. These specialized offerings target high-growth segments, but their current market penetration is modest, necessitating continued investment to achieve widespread adoption and establish market leadership.
BCG Matrix Data Sources
Our BCG Matrix is informed by Evonik's official annual reports and investor relations data, supplemented by independent market research and industry growth forecasts.
